Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
Last trade$72.94
Day change-$1.835 (-2.45%)
Day range$72.30 – $74.54
Volume2,484,277
Market cap$37.02B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.02B
Price / earnings
25.35×
Price / book
1.67×
Price / sales
0.18×
EV / sales
0.16×
EV / EBITDA
8.05×
Profitability
Earnings per share
$2.95
Return on assets
1.84%
Return on equity
6.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.7×
Current ratio
2.63×
Quick ratio
2.63×
Cash ratio
1.28×
Cash flow
Price / cash flow
7.84×
Price / free cash flow
9.39×
Free cash flow
$3.94B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CNC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$50.65B
$54.01B
$50.35B
$50.09B
$49.69B
$49.11B
$47B
$41.15B
Cost of revenue
$41.13B
$39.03B
$38.3B
$41.49B
$40.9B
$38.81B
$36.5B
$31.81B
Gross profit
$9.52B
$14.99B
$12.05B
$8.61B
$8.79B
$10.31B
$10.5B
$9.34B
Selling, general and administrative
$3.24B
$3.1B
$3.4B
$3.37B
$3.15B
$3.04B
$3.35B
$3.23B
Research and development
—
—
—
—
—
—
—
—
Total operating expenses
$50.95B
$52.38B
$48.09B
$51.47B
$56.64B
$49.2B
$45.09B
$40.63B
Operating income
-$306M
$1.64B
$2.26B
-$1.38B
-$6.95B
-$87M
$1.92B
$519M
Interest expense
-$149M
-$153M
-$164M
-$168M
-$170M
-$170M
-$170M
-$172M
Income before taxes
-$122M
$1.49B
$2.1B
-$1.54B
-$6.67B
-$257M
$1.75B
$347M
Income taxes
-$57M
$399M
$560M
-$443M
-$42M
$2M
$432M
$67M
Net income
-$65M
$1.09B
$1.54B
-$1.1B
-$6.63B
-$259M
$1.31B
$280M
Net income attributable to common shareholders
-$71M
$1.09B
$1.54B
-$1.1B
-$6.63B
-$253M
$1.31B
$283M
EBITDA
-$8M
$1.93B
$2.57B
-$534M
$106M
$283M
$2.23B
$833M
Basic earnings per share
-$0.14
$2.21
$3.13
-$2.24
-$13.50
-$0.51
$2.64
$0.57
Diluted earnings per share
-$0.14
$2.19
$3.11
-$2.25
-$13.50
-$0.51
$2.63
$0.56
Recent news
Company coverage with links to the original publishers.
Elevance Health expects Medicaid margins to improve in 2027 through higher reimbursement rates and cost management, with Q3 Medicaid revenues reaching $15 billion. However, rate increases remain uneven across states and may not fully offset elevated medical costs. Peers Centene and Molina face similar pressures, with mixed results in converting premium growth to profitability.
Centene Corporation (CNC) receives a #3 (Hold) rating from Zacks with a VGM Score of A. The healthcare services company has shown positive momentum with shares up 3.1% over the past four weeks and nine analysts revising earnings estimates upward in the last 60 days. The Zacks Consensus Estimate increased to $5.27 per share with an average earnings surprise of +248.9%.
The Invesco S&P 500 Pure Value ETF (RPV) is reviewed as a reasonable option for large cap value exposure with a 0.35% expense ratio and $1.79 billion in assets. The ETF has gained 20.23% year-to-date and 25.22% over the past year, with a medium risk profile. However, competitors like Vanguard Morningstar Value ETF (VTV) and Schwab U.S. Dividend Equity ETF (SCHD) offer lower expense ratios and significantly larger asset bases.
Invesco S&P 500 Pure Value ETF (RPV) is a passively managed large-cap value ETF with $1.79 billion in assets and a 0.35% expense ratio. The fund has returned 20.23% year-to-date and 25.22% over the past year, with a medium risk profile (beta 0.83). It carries a Zacks ETF Rank of 3 (Hold) and is positioned as a sufficient option for large-cap value exposure, though competitors like Vanguard Morningstar Value ETF (VTV) and Schwab U.S. Dividend Equity ETF (SCHD) offer lower expense ratios.
With Democrats potentially returning to power in Congress, health insurers focused on the ACA marketplace like Oscar Health and Centene could benefit from restored government subsidies for lower-income payers. These subsidies expired earlier in 2026, causing significant member churn. Healthcare cost inflation and potential subsidy reinstatement could drive premium growth and profitability for these insurers, though risks include potential nationalized health insurance policies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.